Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group

Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group

Abstract Background Even clearly resectable pancreatic cancer still has an unfavorable prognosis. Neoadjuvant or perioperative therapies might improve the prognosis of these patients. Thus, evaluation of perioperative chemotherapy in resectable pancreatic cancer in a prospective, randomized trial is...

Full description

Bibliographic Details
Main Authors: Thomas J. Ettrich, Andreas W. Berger, Lukas Perkhofer, Severin Daum, Alexander König, Andreas Dickhut, Uwe Wittel, Kai Wille, Michael Geissler, Hana Algül, Eike Gallmeier, Jens Atzpodien, Marko Kornmann, Rainer Muche, Nicole Prasnikar, Andrea Tannapfel, Anke Reinacher-Schick, Waldemar Uhl, Thomas Seufferlein
Format: Article
Language:English
Published: BMC 2018-12-01
Series:BMC Cancer
Subjects:
Pancreatic ductal adenocarcinoma
Pancreatic cancer
Resectable
Neoadjuvant chemotherapy
Perioperative chemotherapy
Online Access:http://link.springer.com/article/10.1186/s12885-018-5183-y

Internet

http://link.springer.com/article/10.1186/s12885-018-5183-y

Similar Items